Search Results
Jul 08, 2026, 10:00 ET Linus Health AAIC Studies Advance Alzheimer's Care: Earlier Detection, More Confident Diagnosis, and Patient-Centered Measurement
Alzheimer's Association International Conference® (AAIC®) 2026, taking place July 12-15 in London and online.
More news about: Linus Health
Jul 07, 2026, 09:00 ET Neurophet Showcases 'Neurophet AQUA AD Plus' at AAIC 2026, Expands Global Partnerships
Jake Junkil Been, Co-CEO of Neurophet. "Through our participation in AAIC 2026, we plan to further accelerate the expansion of strategic partnerships with global pharmaceutical companies and CROs in the ICL sector."Meanwhile, AAIC 2026 is the world's largest international conference dedicated to
More news about: Neurophet
Jul 07, 2026, 03:00 ET Beckman Coulter Diagnostics Expands Alzheimer's Portfolio with CE-Marked p-Tau217 Blood Test and New High-Specificity Research Assay
expansion into emerging markers across neurodegenerative diseases as scientific understanding evolves.Beckman Coulter Diagnostics at AAIC 2026At AAIC 2026 in London, Beckman Coulter Diagnostics will highlight new data advancing blood-based testing for Alzheimer's disease through a focused
More news about: Beckman Coulter Inc
Jul 06, 2026, 08:00 ET Cumulus Neuroscience and Muse by Interaxon Bring Validated At-Home Sleep EEG to CNS Clinical Trials
multi-modal suite for central nervous system (CNS) clinical trials. The collaboration debuts at the Alzheimer's Association International Conference (AAIC) 2026 in London, July 12–15.
More news about: Cumulus Neuroscience
Jun 30, 2026, 02:53 ET New clinical and real-world evidence on Lecanemab to be presented at AAIC conference 2026
B) partner Eisai will present new clinical and real-world evidence on lecanemab (Leqembi®) at the Alzheimer's Association International Conference (AAIC) in London, July 12-15, including data on its subcutaneous formulation, long-term use across diverse patient groups, maintenance dosing, and at-home
More news about: BioArctic
Jun 30, 2026, 02:44 ET New clinical and real-world evidence on Lecanemab to be presented at AAIC conference 2026
B) partner Eisai will present new clinical and real-world evidence on lecanemab (Leqembi®) at the Alzheimer's Association International Conference (AAIC) in London, July 12-15, including data on its subcutaneous formulation, long-term use across diverse patient groups, maintenance dosing, and at-home
More news about: BioArctic
Jun 29, 2026, 07:30 ET Eisai to Showcase Alzheimer's Disease Portfolio with More Than 50 Presentations at the Alzheimer's Association International Conference® 2026 (AAIC®)
(E2814), at the Alzheimer's Association International Conference® 2026 (AAIC®) from July 12-15 in London and online. Eisai will present 52 abstracts across its AD portfolio at AAIC. Highlights include a Developing Topics Session and a Featured Research Session on lecanemab,
More news about: Eisai Inc.
Jun 22, 2026, 05:14 ET ChemDiv, Inc. Highlights Successful Deployment of Proprietary CNS Drug Discovery Platform, Advancing Neurodegenerative Programs for Polku Therapeutics and Brenig Therapeutics
and Polku Therapeutics is scheduled to present new research from its PREP-targeting platform at the Alzheimer's Association International Conference (AAIC) on July 12, 2026.By successfully facilitating the translation of novel biological targets into viable therapeutic candidates for both Brenig
More news about: ChemDiv, Inc
May 27, 2026, 10:00 ET Linus Health Digital Cognitive Assessments Meet or Surpass New CEOi Benchmarks for Early Cognitive Impairment Detection
presentation at the Alzheimer's Association International Conference [AAIC] 2026), directly supporting the CEOi recommendation that brief
More news about: Linus Health
May 14, 2026, 20:48 ET The ADDF Highlights Encouraging Progress Toward Targeting Multiple Alzheimer's Pathologies in Biogen's Phase 2 Tau Study
the disease in tandem.Topline data from the CELIA study will be presented at the upcoming Alzheimer's Association International Conference (AAIC), taking place July 12-16, 2026, in London.About The Alzheimer's Drug Discovery Foundation (ADDF)Founded in 1998 by Leonard A. and
More news about: Alzheimer's Drug Discovery Foundation
Apr 08, 2026, 09:00 ET Peer Reviewed Study Validates Creyos as a Faster, More Sensitive Approach to Dementia Detection in Primary Care
Alzheimer's Association International Conference (AAIC), emerging clinical perspectives signaled growing limitations of traditional tools like the MoCA in primary care, alongside increased recognition of
More news about: Creyos
Dec 04, 2025, 10:27 ET EL PROGRAMA ESTRUCTURADO DE ESTILO DE VIDA SALUDABLE POINTER DE EE. UU., EL CUAL YA HA DEMOSTRADO MEJORAR LA COGNICIÓN, TAMBIÉN PUEDE MEJORAR LA APNEA DEL SUEÑO, LA REGULACIÓN DE LA PRESIÓN ARTERIAL Y LA RESILIENCIA COGNITIVA
Conferencia Internacional de la Alzheimer's Association de 2025 (AAIC 2025). La intervención de estilo de vida multicomponente basada en la evidencia adaptada para la población de EE. UU. consiste en ejercicio físico regular,
More news about: Alzheimer's Association
Dec 04, 2025, 10:24 ET O PROGRAMA ESTRUTURADO DE ESTILO DE VIDA SAUDÁVEL US POINTER -- QUE JÁ DEMONSTROU SER CAPAZ DE MELHORAR A COGNIÇÃO -- TAMBÉM PODE MELHORAR A APNEIA DO SONO, A REGULAÇÃO DA PRESSÃO ARTERIAL E A RESILIÊNCIA COGNITIVA
AAIC 2025. A intervenção de estilo de vida multicomponente, baseada em evidências, adaptada para a população dos EUA, consiste em exercícios físicos
More news about: Alzheimer's Association
Dec 03, 2025, 15:43 ET U.S. POINTER 結構化健康生活方式計劃----早前已證明可改善認知能力，也可能改善睡眠呼吸中止症、血壓調節與認知韌性。
AAIC 2025 上報告。為了美國人口而採用的證據為本多組分生活方式干預措施包括：定期進行體能活動、MIND 飲食、透過電腦訓練和其他智力及社交活動而進行認知挑戰，以及定期與研究臨床醫生回顧健康指標和設定目標。阿茲海默症協會科學總監兼醫療事務主管
More news about: Alzheimer's Association
Dec 03, 2025, 07:54 ET U.S. POINTER構造化健康ライフスタイル・プログラム―これまでに認知機能を改善することが示されている同プログラムが睡眠時無呼吸、血圧調節、認知回復力も改善する可能性を示唆
POINTER試験のために作成され、昨年7月にJAMAで最初の結果を発表し、AAIC
More news about: Alzheimer's Association
Dec 02, 2025, 14:52 ET LE PROGRAMME DE MODE DE VIE SAIN STRUCTURÉ DE U.S. POINTER - DONT IL A ÉTÉ DÉMONTRÉ QU'IL AMÉLIORAIT LA COGNITION - PEUT ÉGALEMENT AMÉLIORER L'APNÉE DU SOMMEIL, LA RÉGULATION DE LA TENSION ARTÉRIELLE ET LA RÉSILIENCE COGNITIVE
AAIC 2025. L'intervention sur le mode de vie à plusieurs composantes, fondée sur des données probantes et adaptée à la population américaine, consiste
More news about: Alzheimer's Association
Dec 02, 2025, 14:50 ET DAS U.S. POINTER-PROGRAMM FÜR EINEN GESUNDEN LEBENSSTIL - DAS NACHWEISLICH DIE KOGNITIVEN FÄHIGKEITEN VERBESSERT - KANN AUCH SCHLAFAPNOE, BLUTDRUCKREGULIERUNG UND KOGNITIVE WIDERSTANDSFÄHIGKEIT VERBESSERN
AAIC 2025 vorgestellt wurden. Die evidenzbasierte, an die US-Bevölkerung angepasste Multikomponenten-Lebensstil-Intervention besteht aus regelmäßiger
More news about: Alzheimer's Association
Dec 02, 2025, 14:46 ET El programa de estilo de vida saludable de U.S. Pointer puede mejorar la apnea del sueño
AAIC 2025. La intervención de estilo de vida multicomponente basada en evidencia y adaptada para la población estadounidense consiste en ejercicio físico
More news about: Alzheimer's Association
Dec 02, 2025, 14:00 ET THE U.S. POINTER STRUCTURED HEALTHY LIFESTYLE PROGRAM -- PREVIOUSLY SHOWN TO IMPROVE COGNITION -- MAY ALSO IMPROVE SLEEP APNEA, BLOOD PRESSURE REGULATION, AND COGNITIVE RESILIENCE
AAIC 2025. The evidence-based multicomponent lifestyle intervention adapted for the U.S. population consists of regular physical exercise, the MIND diet,
More news about: Alzheimer's Association
Dec 02, 2025, 14:00 ET THE U.S. POINTER STRUCTURED HEALTHY LIFESTYLE PROGRAM -- PREVIOUSLY SHOWN TO IMPROVE COGNITION -- MAY ALSO IMPROVE SLEEP APNEA, BLOOD PRESSURE REGULATION, AND COGNITIVE RESILIENCE
AAIC 2025. The evidence-based multicomponent lifestyle intervention adapted for the U.S. population consists of regular physical exercise, the MIND diet,
More news about: Alzheimer's Association
Nov 13, 2025, 02:23 ET Interim Report for the period July - September 2025: BioArctic
during the third quarter 2025 New data on lecanemab were presented at the AAIC-congress focused on long-term efficacy and safety, real world evidence and subcutaneous dosing Option, collaboration and
More news about: BioArctic
Nov 13, 2025, 02:19 ET Interim Report for the period July - September 2025: BioArctic
during the third quarter 2025 New data on lecanemab were presented at the AAIC-congress focused on long-term efficacy and safety, real world evidence and subcutaneous dosing Option, collaboration and
More news about: BioArctic
Oct 08, 2025, 07:01 ET Alzheimer's Association and Edward Jones Extend Strategic Alliance Through 2030
End Alzheimer's, Edward Jones will contribute nearly $1 million in 2026 to advance groundbreaking research through the Edward Jones Research Fund and AAIC For All — a public-facing initiative that shares the latest findings in Alzheimer's and dementia research. To date, Edward Jones
More news about: Alzheimer's Association